Enlicitide
As of the edition of 20 October 2026, Enlicitide is a protein: marketed, first approved in 2026 (US); US protection ends in 2040.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Protein
- Brand name
- Lipfendra
- First approved
- 15 July 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Merck & Co.
- Registered trials
- 34, 0 stopped early
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Digestive system; Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2040.
The last listed US drug-substance patent ends in 2040. The application that gives this date is held by Merck & Co..
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 24 | 21 | 3 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 8 | 3 | 5 | 0 |
| All trials | 34 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Originator and Lead sponsor of trials | 2021 to now |